Stocks across software, solar, biotech, education finance and semiconductors moved sharply in early trading after a wave of analyst actions and company-related headlines.
Data compiled from pre-market coverage pointed to broad gains for names such as Salesforce, First Solar, Biogen, Iren and SLM, while IonQ and Micron declined on deal and competition-related news.
Key takeaways
- Salesforce rose about 4% after a Bank of America double upgrade to buy, with the bank arguing artificial intelligence should “deepen dependence” on the software company’s products.
- First Solar climbed about 2.4% following a Truist upgrade to buy, citing growth expectations, strong solar demand and pricing power.
- Biogen advanced about 2% after JPMorgan upgraded the stock to overweight, pointing to multiple clinical readouts in 2027 as potential catalysts.
- Iren jumped about 5.3% on a reported multiyear cloud computing deal with Anthropic, according to The Information.
- IonQ and Micron fell, with IonQ down more than 2% on a reported acquisition of Elisity and Micron down about 2% after China’s CXMT said it will begin producing next-generation memory chips.
What drove the early moves
Several of the day’s largest share-price reactions were tied to upgrades and target repositioning by major brokerages, reflecting changing views on earnings durability and long-term demand.
- Salesforce: The shares gained roughly 4% after Bank of America upgraded the stock from underperform to buy, and reiterated a positive stance through a “double upgrade.” The bank’s central argument was that artificial intelligence would not disrupt Salesforce’s business model, instead reinforcing customer reliance on the company’s platform.
- First Solar: Shares rose about 2.4% after Truist raised its rating to buy from hold. The firm cited expectations for continued growth and strong demand in the solar market, along with what it described as First Solar’s pricing power.
- Biogen: Biogen was up around 2% following a JPMorgan upgrade to overweight from neutral. JPMorgan pointed to multiple clinical readouts scheduled for 2027 as key potential catalysts.
- SLM: The education-loan administrator advanced about 2% after Morgan Stanley upgraded the stock to overweight from equal weight. The bank highlighted valuation as a reason for the upgrade, noting the shares were down about 15% year to date.
- Mattel: The toy maker rose more than 1% after Seaport upgraded the stock to buy from neutral. The research firm connected the move to increased investor attention on toy names amid takeover speculation, arguing that some value may be underappreciated.
Not all the movers were tied to rating changes. A separate set of headlines influenced stocks tied to technology and industrial competition.
- Iren: The Australia-based electricity and cloud-focused company jumped roughly 5.3% after The Information reported that it had quietly signed a multiyear cloud computing deal with Anthropic.
- IonQ: IonQ fell more than 2% after The Wall Street Journal reported the company bought cybersecurity firm Elisity for up to $1.3 billion. The reaction suggested investors were weighing the financial and strategic impact of the acquisition.
- Micron: Micron dropped about 2% after CXMT, a China-based chipmaker, said it will begin producing next-generation memory chips intended to compete for market share with U.S. and Korean suppliers.
Market reaction: upgrades vs. competitive pressure
The early price action underscored the split between investors rewarding renewed confidence in growth and clinical pipelines, and those reacting more cautiously to deal announcements and intensifying memory competition.
For the upgraded names, the common theme was a re-rating driven by either expected demand strength (First Solar), perceived durability of software adoption amid AI (Salesforce), or event-driven catalysts tied to future clinical milestones (Biogen). In contrast, IonQ’s decline followed an acquisition headline that raised questions about integration and capital allocation, while Micron’s drop reflected worries that additional suppliers could pressure pricing and margins in memory markets.
What analysts and headlines imply for investors
Across brokerages, investors appeared to focus on forward visibility—how quickly catalysts could translate into results and whether the businesses can maintain pricing power or expand usage.
- AI and enterprise software: Bank of America’s assessment of AI’s impact on Salesforce suggests investors may be reassessing software adoption risk, with the debate shifting from disruption to reinforcement of platform dependence.
- Solar demand and pricing power: Truist’s rationale for First Solar focused on sustained demand and pricing leverage, implying investors are looking for evidence that supply and demand dynamics will remain supportive.
- Biotech timelines: JPMorgan’s emphasis on 2027 clinical readouts points to a longer-horizon framework, where near-term performance may matter less if the probability-weighted outcomes are viewed as improving.
- Cloud computing partnerships: The reported Anthropic-related deal involving Iren could be interpreted as validation of demand for cloud workloads, though investors will likely seek further details on financial terms and ramp timing.
Bigger picture
Together, the moves reflect how quickly markets can reprice risk when analysts change trajectories on fundamentals—or when new information signals shifting competitive landscapes. With semiconductors in focus and cloud and AI-linked themes continuing to attract attention, investors are likely to remain sensitive to both deal activity and product-cycle announcements.
Looking ahead, traders will likely watch for follow-through on these rating-driven moves as more firms publish research notes and as companies provide updates on guidance and pipeline timelines. For the broader tape, upcoming macro data and central bank messaging—especially anything that influences interest-rate expectations—will remain important for valuations across growth and cyclical sectors.
